Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. (Q51067690)

28 March 2018

title

Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. (English)

1 reference

28 March 2018

23

Gilles Montalescot

1 reference

28 March 2018

21

Farzin Beygui

1 reference

28 March 2018

19

Mathieu Kerneis

1 reference

28 March 2018

5

Guillaume Cayla

1 reference

28 March 2018

11

Patrick Ohlmann

1 reference

28 March 2018

Jean-Philippe Collet

1

object named as

Jean-Philippe Collet

1 reference

28 March 2018

author name string

Johanne Silvain

2

1 reference

28 March 2018

Olivier Barthélémy

3

1 reference

28 March 2018

Grégoire Rangé

4

1 reference

28 March 2018

Eric Van Belle

6

1 reference

28 March 2018

Thomas Cuisset

7

1 reference

28 March 2018

Simon Elhadad

8

1 reference

28 March 2018

François Schiele

9

1 reference

28 March 2018

Nicolas Lhoest

10

1 reference

28 March 2018

Didier Carrié

12

1 reference

28 March 2018

Hélène Rousseau

13

1 reference

28 March 2018

Pierre Aubry

14

1 reference

28 March 2018

Jacques Monségu

15

1 reference

28 March 2018

Pierre Sabouret

16

1 reference

28 March 2018

Stephen A O'Connor

17

1 reference

28 March 2018

Jérémie Abtan

18

1 reference

28 March 2018

Christophe Saint-Etienne

20

1 reference

28 March 2018

Eric Vicaut

22

1 reference

28 March 2018

ARCTIC investigators

24

1 reference

28 March 2018

language of work or name

English

0 references

publication date

15 July 2014

1 reference

28 March 2018

published in

The Lancet

1 reference

28 March 2018

volume

384

1 reference

28 March 2018

page(s)

1577-1585

1 reference

28 March 2018

issue

9954

1 reference

28 March 2018

2013 ESC guidelines on the management of stable coronary artery disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Guidelines on myocardial revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Dual Antiplatelet Therapy Duration and Clinical Outcomes Following Treatment With Zotarolimus-Eluting Stents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Duration of dual antiplatelet therapy after implantation of drug-eluting stents.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Bedside monitoring to adjust antiplatelet therapy for coronary stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

1 reference

7 January 2021

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous co

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960612-7

7 January 2021

10.1016/S0140-6736(14)60612-7

Identifiers

DOI

1 reference

28 March 2018

PubMed ID

25037988

1 reference

28 March 2018